DA-JC4

**DA-JC4** is a dual agonist of the glucagon-like peptide 1 receptor (GLP-1R) and the gastric inhibitory polypeptide receptor (GIPR), designed as a chemical (non-biologic) compound. It functions by activating both GLP-1 and GIP receptors as a full agonist, mimicking the native hormones, but with improved blood-brain barrier penetration compared to existing GLP-1 analogues. DA-JC4 has demonstrated neuroprotective effects in preclinical models of neurodegenerative diseases, notably Alzheimer's disease (AD) and Parkinson's disease (PD). It reduces neuroinflammation, protects dopaminergic neurons, decreases mitochondrial stress, rescues synaptic plasticity, lowers tau phosphorylation and amyloid plaque load, and re-sensitizes brain insulin signaling pathways. These effects are partly mediated through modulation of the AKT/JNK signaling pathway. DA-JC4 is being developed primarily for neurodegenerative and metabolic indications, including Alzheimer's disease, Parkinson's disease, and type 2 diabetes[1][2][5].